Physician profile
Bassem B Ibrahim
NPI 1346683505
$1,293.67
in general payments reported to CMS, 2019-2025
24 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.36 · 2020: $125 · 2021: $103 · 2022: $334 · 2023: $390 · 2024: $145 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.71 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.15 | 2019-2023 | Farxiga |
| Mallinckrodt Hospital Products INC. | $215.80 | 2022-2024 | Acthar |
| Calliditas Therapeutics US INC. | $108.49 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $108.03 | 2023 | Jynarque |
| Amgen INC. | $78.19 | 2019-2024 | Krystexxa, Tavneos |
| Boston Scientific Corporation | $66.95 | 2024-2025 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $56.10 | 2020-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $49.48 | 2020 | |
| Pfizer INC. | $36.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $33.02 | 2025 | Ultomiris |
| Ucb, INC. | $27.44 | 2025 | Rystiggo |
| Horizon Therapeutics Plc | $27.00 | 2022 | |
| Lundbeck LLC | $25.65 | 2025 | Vyepti |
| Daiichi Sankyo INC. | $23.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.07 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.50 | 2021 | |
| Radius Health, INC. | $19.85 | 2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $19.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.56 | 2022 | |
| Shionogi INC | $14.98 | 2025 | Fetroja |
| Tanabe Pharma America, INC. | $14.68 | 2020 | |
| Aurinia Pharma U.S., INC. | $14.22 | 2022 | |
| Melinta Therapeutics, LLC | $13.54 | 2022 | |
| Mayne Pharma Commercial LLC | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.